An increasing number of individuals are turning to OpenAI's ChatGPT and other Large Language Models (LLMs) for health-related inquiries, often discovering surprisingly valuable medical insights from these chatbots.
KJ Dhaliwal, known for selling the South Asian dating app Dil Mil for $50 million in 2019, has long been driven by the inefficiencies of the U.S. healthcare system, a concern stemming from his childhood experiences as a medical translator for his parents. He recognized the emergence of LLMs as a pivotal opportunity to address these systemic issues.
In May 2024, Dhaliwal launched Lotus Health AI, a complimentary primary care provider offering 24/7 availability in 50 languages. This Tuesday, Lotus announced a successful $35 million Series A funding round, co-led by prominent venture capital firms CRV and Kleiner Perkins, elevating its total funding to $41 million.
While people are already consulting AI for health advice, Lotus Health AI distinguishes itself by transcending basic conversational support. It facilitates actual medical care, encompassing diagnoses, prescriptions, and specialist referrals, thereby moving beyond simple AI chats.
Fundamentally, Lotus is constructing an AI-driven medical practice that mirrors a traditional clinic, complete with licenses to operate across all 50 states, comprehensive malpractice insurance, HIPAA-compliant systems, and full access to patient records.
The core distinction lies in the fact that the majority of the medical work is executed by AI, which is specifically trained to replicate the questioning process of a human physician.
Recognizing that AI models can be prone to "hallucinations," Lotus Health AI maintains a crucial safeguard: all final diagnoses, lab orders, and medical prescriptions are rigorously reviewed by board-certified human doctors from esteemed health institutions such as Stanford, Harvard, and UCSF.
Lotus has engineered an AI model capable of synthesizing the most current evidence-based research with a patient’s medical history and clinical responses to formulate a comprehensive treatment plan, similar to approaches seen in advanced medical information platforms.
"AI is giving the advice, but the real doctors are actually signing off on it," Dhaliwal confirmed in an interview with TechCrunch.
Lotus acknowledges the inherent limitations of virtual care. For urgent health concerns, the platform directs patients to the nearest urgent care center or emergency room. Furthermore, if a case necessitates a physical examination, Lotus refers the patient to an in-person physician, as Dhaliwal elaborated.
Entrusting such a substantial portion of medical decision-making to AI represents an ambitious venture, particularly given the intricate regulatory landscape of healthcare. For instance, physicians are legally restricted to treating patients only within the states where they hold a valid license.
As CRV general partner Saar Gur, who led the investment and joined the company’s board, articulated: "There are many challenges, but it’s not SpaceX sending astronauts to the moon."
Gur, an early investor in successful companies like DoorDash, Mercury, and Ring, is confident that the telemedicine frameworks solidified during the pandemic, coupled with recent advancements in AI, provide Lotus with the necessary tools to navigate many of the existing regulatory and engineering obstacles.
"It’s a big swing," Gur remarked. However, for an investor like Gur, that audacious goal is precisely the appeal: Lotus’s endeavor to fundamentally redefine the entire primary care model.
At a time when primary care physicians are in short supply, Lotus asserts its capacity to serve ten times as many patients as a conventional practice, even while limiting each virtual visit to 15 minutes.
While Lotus is not the sole innovator in the AI doctor space, with Lightspeed-backed Doctoronic being a notable competitor, Lotus distinguishes itself by currently offering its care entirely free of charge.
Dhaliwal indicated that future business models might incorporate sponsored content or subscriptions, but the immediate focus remains squarely on product development and patient acquisition rather than revenue generation.
The Editorial Staff at AIChief is a team of professional content writers with extensive experience in AI and marketing. Founded in 2025, AIChief has quickly grown into the largest free AI resource hub in the industry.